ANAPTYSBIO, INC — Director's Dealing 2017

Feb 1, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2017-01-31

Reporting Person: Novo A/S (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-31	Common Stock	C	1428571	—	Acquired	1428571	Direct
2017-01-31	Common Stock	C	486820	—	Acquired	1915391	Direct
2017-01-31	Common Stock	C	312986	—	Acquired	2228377	Direct
2017-01-31	Common Stock	C	673454	—	Acquired	2901831	Direct
2017-01-31	Common Stock	X	81673	—	Acquired	2983504	Direct
2017-01-31	Common Stock	P	50000	$15.00	Acquired	3033504	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-31	Series B Preferred Stock	$	C	1428571	Disposed		Common Stock (1428571)	Direct
2017-01-31	Series C Preferred Stock	$	C	486820	Disposed		Common Stock (486820)	Direct
2017-01-31	Series C-1 Preferred Stock	$	C	312986	Disposed		Common Stock (312986)	Direct
2017-01-31	Series D Preferred Stock	$	C	673454	Disposed		Common Stock (673454)	Direct
2017-01-31	Series C Preferred Stock Warrant (Right to Buy)	$4.55	X	117235	Disposed	2018-11-04	Common Stock (117235)	Direct

Footnotes

F1: The Series B Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock (the "Preferred Stock") had no expiration date and was convertible at any time at the holder's election. Immediately prior to the closing of the Issuer's initial public offering (the "IPO Closing"), the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.

F2: Immediately prior to the IPO Closing, the warrant became exercisable for shares of common stock. The shares acquired upon exercise of the warrant were acquired through a net exercise procedure in accordance with the terms of the warrant and did not involve any sale of shares. All shares received upon such exercise are subject to a lock-up agreement between the Reporting Person and the underwriters.

F3: Represents a purchase from the underwriters in the Issuer's initial public offering.